Methods and Results
We studied the effect of VEGF on collateral blood flow in dogs subjected to gradual occlusion of the left circumflex coronary artery (LCx). Beginning 10 days after placement of an LCx-constricting device, VEGF 45 ,ug (n=9) or saline (n= 12) was administered daily via an indwelling catheter in the distal LCx, at a point just beyond the occlusion. Treatment was maintained for 28 days. Collateral blood flow was determined with microspheres 7 days before treatment, immediately before treatment (day 0), and 7, 14, 21, and 28 days into the treatment period. Collateral blood flow was quantified during chromonar-induced maximal vasodilation and expressed as a collateral zone/normal zone (CZINZ) ratio. Treatment with VEGF was associated with a 40% increase in collateral blood flow (final CZ/NZ blood flow ratios of 0.49+0.06 and 0.35±0.02 in the VEGF-treated and control groups, respectively, P=.0037) as well as an 89% increase in the numerical density of intramyocardial distribution vessels (>20 ,um diameter) in the CZ (6.6±1.4 versus 3.5 ±0.7 vessels/ mmn in VEGF-treated and control dogs, respectively, P<.05).
Conclusions We conclude that intracoronary VEGF enhances the development of small coronary arteries supplying ischemic myocardium, resulting in marked augmentation of maximal collateral blood flow delivery. These results demonstrate the feasibility of pharmacological enhancement of collateral growth and suggest a new therapeutic approach for the treatment of myocardial ischemia. (Circulation. 1994 ;89: C oronary collaterals improve myocardial blood flow and preserve myocardial function in the condition of coronary obstruction. The presence of collateral vessels ameliorates myocardial ischemia, and well-developed collaterals diminish the functional derangements that occur as a consequence of acute coronary occlusion.1.2 In dogs, gradual occlusion of a major coronary artery induces collateral formation.3 In general, the resulting collateral blood flow provides adequate metabolic support under resting conditions and is sufficient to prevent myocardial infarction; however, maximal blood flow is compromised.
Under conditions of increased metabolic demand or during pharmacologically induced coronary vasodilation, the expected increase in blood flow in the collateral-dependent area is blunted, creating a disparity between the normally perfused and collateral-perfused areas.
Vascular endothelial growth factor (VEGF) is a heparin-binding growth factor that is angiogenic in vivo, possessing unique target cell specificity for vascular endothelial cells.4-6 A 46-kDa homodimeric peptide, VEGF was originally purified from media conditioned by bovine pituitary folliculostellate cells. VEGF is structurally related to the A and B chains of PDGF, and the protein was purified independently as vascular permeability factor, a glycoprotein that promotes vascular fluid and protein extravasation.7 Unlike acidic and basic fibroblast growth factors, the VEGF sequence is preceded by a signal peptide, a characteristic consistent with extracellular secretion.8 High-affinity VEGF binding sites have been localized to endothelial cells in adult rat tissue sections,9 and expression of VEGF mRNA has been shown to be related temporally and spatially to physiological angiogenesis in a number of cell types in the murine female reproductive system.10 Moreover, VEGF mRNA levels are reversibly increased in cultured cells subjected to hypoxia,11 and VEGF has been reported to be expressed by cardiac myocytes in response to ischemia in vitro and in vivo.12 Together, these findings suggest that the peptide is a regulator of angiogenesis under physiological conditions as well as during the adaptive response to pathological states. We speculated that in the setting of progressive coronary occlusion, exogenously administered VEGF would accelerate myocardial angiogenesis, thereby improving collateral blood flow, and tested this hypothesis in a canine model.
Methods
The experimental methods were approved by the Animal Care and Use Committee of the National Heart, Lung, and 
Microsphere Blood Flow Measurements
Microsphere blood flow studies were performed with the animal in the conscious state during maximal coronary vasodilatation. Myocardial blood flow studies were conducted weekly: The first two determinations were made before randomization to treatment, and four subsequent determinations were made during the treatment period. Thus, collateral blood flow was quantified 3, 10, 17, 24, 31, and 38 days after ameroid placement. Chromonar 8 mg/kg (Hoechst-Roussel Pharmaceuticals) was administered into the left atrial catheter to effect maximal coronary vasodilatation. This dose elicits a four-to fivefold increase in myocardial blood flow and abolishes the reactive hyperemic response to 20-second coronary occlusions without an appreciable effect on arterial blood pressure.14'15 Approximately 3 x 106 radiolabeled microspheres, 15 gum in diameter, were injected into the left atrial catheter as described previously.16 A different isotope was randomly selected each week: 141Ce, "3Sn, 8ISr, 95Nb, 46Sc (New England Nuclear), or '2I, (3M Co). Collateral blood flow was expressed as the ratio of collateral zone (CZ) to normal zone (NZ) blood flow, CZNZ. During the first few weeks after ameroid placement, arterial constriction was incomplete, and LCx flow was only partially arrested; thus, CZ blood flow was the sum of residual antegrade LCx flow and collateral flow (provided primarily through anastomoses originating from the left anterior descending coronary artery). Thus, for microsphere determinations of CZ blood flow, the LCx hydraulic balloon occluder was temporarily inflated to interrupt antegrade LCx flow such that collateral flow alone could be quantified. In addition, the balloon occluder was permanently inflated on day 24 to ensure complete and timely LCx occlusion.
Tissue Preparation
Animals were killed with an overdose of sodium pentobarbital and KCl. The myocardium was preserved using perfusion fixation with McDowell-Trump solution at physiological pressure. 17 It was verified that the proximal LCx was encircled by the ameroid constrictor and that the vessel was completely occluded. Three central short-axis slices were removed from the left ventricle, and each was divided into eight circumferential wedges that were further subdivided into endocardial and epicardial portions. The midequatorial slice and a second slice on the apical side of the central slice were used for microsphere blood flow analysis (Fig 2A) . A third slice (to the base of the central slice) was used for estimation of myocardial infarct size. Based on plots of blood flow versus position ( Fig  2B) , two CZ wedges and two NZ wedges were selected from each slice for further analysis, as we have done previously.16
Thus, four CZ and four NZ transmural wedges were used to compute mean CZ and NZ blood flow, respectively, and vascular density was quantified in these samples.
Vascular density was assessed in tissue sections using computer-based image analysis. Samples were embedded in glycol methacrylate. Two-micrometer sections were stained with toluidine blue and examined using a microscope interfaced with a video camera and computer-controlled motorized stage, such that each slide was systematically analyzed in its entirety. Each section was examined at x40, x 10, x4, and with a macro lens to match system magnification with the size of the object(s) to be detected. Thus, vessels .10 ,um in diameter were considered to be capillaries, and capillary density was determined using a x40 objective lens. Vessels 20 to 60 Am in diameter were quantified at x 10, and vessels 60 to 120 ,um, 120 to 180 tlm, and >180 pum were analyzed at x4. Total tissue area, quantified using a macro lens, served as the denominator for all vessels. Vascular profiles were discriminated and counted using a computer-based image analysis system (Advanced Imaging Concepts, Inc). For determination of vascular density, hearts were perfusion-fixed at physiological pressure. Given that the LCx was occluded, the CZ could be subjected to lower perfusion pressure than the NZ during this process, which could lead to some underestimation of vascular density in the CZ. Thus, we believe that comparisons between groups are valid (CZ of treated versus CZ of control, NZ of treated versus NZ of control), whereas direct comparisons between CZ and NZ are not.
Capillaries
In the CZ, capillary density (vessel diameter .10 gm) was 4030±280 and 3970±350 vessels/mm2 in VEGF-treated and control dogs, respectively (P=NS). Likewise, NZ capillary density was similar in VEGFtreated and control dogs (4260±230 versus 4830±250 vessels/mm2, respectively, P=NS) (see Fig 4, left) .
Distribution Vessels
The numerical vascular density of distribution vessels (diameter >20 gum) was 6.5±1. dium, and the increase in vascular density was not restricted to any one size range of vessels analyzed.
In Vitro Studies
The mitogenic effect of VEGF on canine arterial endothelial and smooth muscle cells in vitro is illustrated in Fig 5. Basic FGF, a nonselective mesenchymal cell mitogen, was used as a positive control for smooth muscle cells and endothelial cells. Both VEGF and basic FGF potentiated the proliferation of canine arterial endothelial cells, and basic FGF was approximately twice as potent as VEGF (Fig 5, top) . Unlike basic FGF, VEGF was not mitogenic for canine arterial smooth muscle cells, confirming the selectivity of VEGF for endothelial cells (Fig 5, bottom) .
Discussion
As coronary artery narrowing progresses, myocardial viability and the extent of myocardial functional derangement are inextricably related to the capacity of collateral vessels.1,2 Collateral development is incompletely understood: Mechanical factors, chemical mediators, and angiogenic growth factors all have been implicated in the process.ll1l9-23 In the setting of progressive coronary occlusion, the augmented transcollateral pressure gradient leads to increased flow across collateral vessels, with attendant increases in radial wall tension and shear stress. These changes by themselves or possibly accompanied by metabolic alterations in hypoperfused tissue could lead to synthesis or release of peptide growth factors or upregulation of their receptors. Such growth factor-receptor interactions are postulated to play an active role in stimulating cellular proliferation and locomotion, requisites of new vessel growth. We hypothesized that intracoronary administration of VEGF, a potent, endothelial cell-specific angiogenic growth factor, would enhance the formation of coronary collaterals during the complex circumstances induced by coronary occlusion. Our results demonstrate that treatment with exogenous VEGF augments the angiogenic process induced by coronary occlusion: VEGF administration was associated with a 40% increase in collateral blood flow after 4 weeks of treatment as well as an 89% increase in the numerical density of intramyocardial distribution vessels (ie, vessels larger than capillaries).
The mechanism of action of the peptide cannot be deduced from our data. VEGF is a potent inducer of vascular permeability,7 and the peptide has been found to express interstitial collagenase in endothelial cells; both properties facilitate cell migration, a crucial step in the angiogenic process. Using canine arterial endothelial and smooth muscle cells, we found that the mitogenic effects of VEGF were specific for vascular endothelial cells in vitro (Fig 5) , confirming that the results of previous studies using cells derived from other species are also applicable to canine cells. 4 Administration of VEGF enhanced the development of coronary arteries supplying collateral-dependent myocardium; however, the role of ischemia and the potential effect of VEGF on normal myocardium are matters of speculation. A recent investigation in miniswine subjected to ameroid-induced LCx occlusion demonstrated that the presence of ischemia is not a prerequisite for the development of collaterals, consistent with the concept that local factors (ie, increased endothelial stretch or shear) are responsible for collateral development.28 It is possible that such events may render the endothelium responsive to exogenous VEGF; alternatively, it is possible that VEGF could exert an angiogenic effect in the absence of ischemia and/or increased shear stress. If so, the peptide could lead to increased vascularity without an appreciable effect on blood flow, and it would be interesting to evaluate the effect of VEGF on coronary blood flow in the normal myocardium.
In the present study, blood flow measurements were obtained during maximal coronary vasodilatation to increase the sensitivity of the analysis and, most importantly, to eliminate autoregulatory influences that could confound the interpretation of the data. In the maximally vasodilated state, vascular tone is reduced to an absolute minimum. Therefore, at any level of arterial pressure, coronary blood flow is limited exclusively by anatomic determinants of vascular resistance. Thus, the increase in collateral blood flow in treated dogs could not be the result of a vasodilator property of VEGF because blood flow was determined in a state of maximum vasodilatation at all times. In addition, we observed an 89% increase in the numerical density of intramyocardial distribution vessels in the CZ of VEGFtreated dogs, providing the anatomic correlate of the increase in maximal collateral blood flow found in these dogs.
Under conditions of maximal coronary vasodilatation, perfusion to the territory of the occluded LCx is dependent on the series resistance of collateral vessels and the coronary microvasculature. The microsphere perfusion measurements used in this study provide an assessment of total CZ vascular resistance but do not distinguish between its individual components. The detection of an increased number of intramyocardial distribution vessels in the CZ of VEGF-treated dogs suggests that the decrease in overall resistance resulted at least in part from alterations within the microvasculature. In future studies, these two resistive components could be discriminated by performing coronary blood flow measurements using an isolated heart preparation.29
We obtained measurements of coronary perfusion on a serial basis; however, an inherent limitation of our study design was that anatomic evidence of neovascularization could be obtained only once: at the conclusion of the study and subsequent to the period of peak vascular growth. Undoubtedly, the increased number of small coronary distribution vessels in VEGF-treated dogs had a salutary effect on myocardial perfusion; however, the experimental design was such that it was not possible to determine whether the increase in small coronary arteries resulted from the radial growth of preexisting arterioles or, alternatively, whether they originated de novo as a result of vascular sprouting.
The results we report, demonstrating a major effect of VEGF on increasing collateral flow to ischemic myocardium, were obtained in a canine model. It must be emphasized that the canine coronary circulation differs in several respects from that of humans.3" Dogs have a strong tendency to develop collaterals in response to gradual coronary occlusion, such that resting collateral flow is normal or near normal; however, maximal perfusion is compromised. Thus, at the end of our study, maximal collateral flow in untreated dogs was only 35% of normal. Such a deficit allows the detection of the angiogenic effects of an intervention, as demonstrated in the present study. Another factor to consider about our model is that VEGF was administered during a period of active collateral growth. In the setting of chronic coronary insufficiency (in humans), when collateral growth has reached a plateau and vascular proliferation has ceased, it is possible that VEGF would not exert a positive effect. Nonetheless, these results suggest a novel and potentially important therapeutic approach to patients with ischemic heart disease; it remains to be established, however, whether VEGF will exert a salutary effect on collateral blood flow in humans.
